Trulicity vs Ozempic: A Clinical Comparison for 2026
Trulicity vs Ozempic: compare efficacy, weight loss, cardiovascular outcomes, side effects, and cost in this evidence-based clinical guide with 6 scientific citations.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 17, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly injectable GLP-1 receptor agonists widely prescribed for type 2 diabetes and, increasingly, weight management. As two of the most prescribed medications in their class, they share a mechanism of action yet differ meaningfully in efficacy, cardiovascular protection, and tolerability.
Choosing between them is not simply a matter of preference — the clinical data reveals important differences that can guide treatment decisions based on individual patient goals.
Evidence: "At both low and high doses, semaglutide was superior to dulaglutide in improving glycaemic control and reducing bodyweight, enabling a significantly greater number of patients with type 2 diabetes to achieve clinically meaningful glycaemic targets." — Pratley RE, et al. Lancet Diabetes Endocrinol. 2018. DOI: 10.1016/S2213-8587(18)30024-X
How Trulicity and Ozempic Work
Both medications activate GLP-1 receptors in the pancreas, gut, and brain. This shared mechanism produces overlapping effects: enhanced insulin secretion in response to meals, suppressed glucagon release, delayed gastric emptying, and reduced appetite via central satiety pathways.
Despite this common pharmacology, structural differences between dulaglutide and semaglutide influence their potency and duration of receptor engagement, which explains why clinical outcomes diverge — particularly for weight loss.
Key Pharmacological Differences
| Feature | Trulicity (Dulaglutide) | Ozempic (Semaglutide) |
|---|---|---|
| Molecule type | GLP-1 analogue fused to IgG4 Fc | GLP-1 analogue (C18 fatty acid) |
| Half-life | ~5 days | ~7 days |
| Approved doses | 0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg | 0.5 mg, 1.0 mg, 2.0 mg |
| Injection device | Single-use auto-injector pen | Multi-dose pen |
| FDA approvals | T2DM, CV risk reduction | T2DM, CV risk reduction |
| Obesity indication | No (Wegovy is semaglutide 2.4 mg) | No (Wegovy is the branded obesity dose) |
Blood Sugar Control: How Do They Compare?
Both agents reduce HbA1c significantly compared to placebo, but head-to-head evidence favors semaglutide.
The SUSTAIN 7 trial — a 40-week randomized, open-label phase 3b study of 1,201 adults with type 2 diabetes on metformin — directly compared semaglutide and dulaglutide:
- Semaglutide 0.5 mg reduced HbA1c by 1.5% vs dulaglutide 0.75 mg at 1.1%
- Semaglutide 1.0 mg reduced HbA1c by 1.8% vs dulaglutide 1.5 mg at 1.4%
A 2024 systematic review and meta-analysis of all available head-to-head studies confirmed these findings, noting that while both drugs achieve clinically meaningful glycemic control, the difference in absolute HbA1c reduction tends to favor semaglutide — particularly at higher doses.
Evidence: "No statistically significant difference in glycemic control achievement between semaglutide and dulaglutide was observed, though semaglutide demonstrated higher efficacy in inducing weight loss." — Meta-analysis. Biomed Rep. 2025. DOI: 10.3892/br.2024.1913
Weight Loss: Ozempic Shows a Clear Advantage
For patients with concurrent overweight or obesity, the weight loss difference between these two drugs is clinically significant.
Weight Reduction in SUSTAIN 7
| Dose comparison | Semaglutide | Dulaglutide | Difference |
|---|---|---|---|
| Low dose | −4.6 kg | −2.3 kg | −2.3 kg favor semaglutide |
| High dose | −6.5 kg | −3.0 kg | −3.5 kg favor semaglutide |
Semaglutide produced roughly twice the weight loss of dulaglutide at both dose levels. This difference is not trivial — for a patient weighing 100 kg, an additional 3.5 kg of weight reduction translates to meaningful improvements in metabolic risk factors, including blood pressure, triglycerides, and insulin sensitivity.
A 2023 Japanese multicenter randomized trial (the COMING study) further supported this pattern: reductions in BMI and visceral fat area were significantly greater with semaglutide than dulaglutide over 24 weeks.
Evidence: "Reductions in body mass index and visceral fat area were significantly more pronounced in the semaglutide group compared with the dulaglutide group at 24 weeks." — COMING study. J Diabetes Investig. 2023. PubMed
Cardiovascular Outcomes: Both Offer Protection
Cardiovascular protection is a major clinical priority for patients with type 2 diabetes. Both Trulicity and Ozempic have demonstrated cardiovascular benefit in large dedicated outcomes trials.
Semaglutide: SUSTAIN-6
The SUSTAIN-6 trial enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk and followed them for 2 years. Semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 26% compared to placebo (HR 0.74; 95% CI 0.58–0.95).
Evidence: "The rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo." — Marso SP, et al. N Engl J Med. 2016. DOI: 10.1056/NEJMoa1607141
Dulaglutide: REWIND
The REWIND trial was the largest and longest cardiovascular outcomes trial for any GLP-1 agonist. It followed 9,901 patients for a median of 5.4 years. Dulaglutide reduced the primary MACE composite endpoint by 12% compared to placebo (HR 0.88; 95% CI 0.79–0.99).
Notably, 32% of REWIND participants had no prior cardiovascular disease — making it the only GLP-1 cardiovascular trial to demonstrate benefit in a predominantly primary prevention population.
Evidence: "The primary composite outcome of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes occurred in 12.0% of dulaglutide participants vs 13.4% of placebo participants (HR 0.88, p=0.026)." — Gerstein HC, et al. Lancet. 2019. DOI: 10.1016/S0140-6736(19)31149-3
Cardiovascular Comparison Summary
| Outcome | Semaglutide (SUSTAIN-6) | Dulaglutide (REWIND) |
|---|---|---|
| MACE reduction | 26% (HR 0.74) | 12% (HR 0.88) |
| Follow-up | 2 years | 5.4 years |
| Primary prevention population | No | Yes (32% of sample) |
| All-cause mortality benefit | Not established | Not established |
Both drugs reduce cardiovascular events. Semaglutide shows a numerically larger MACE reduction in secondary prevention; dulaglutide has unique evidence in primary prevention.
Side Effects and Tolerability
The side effect profiles of Trulicity and Ozempic are similar — gastrointestinal (GI) effects dominate both.
Common Side Effects
| Side Effect | Trulicity | Ozempic |
|---|---|---|
| Nausea | 12–21% | 15–44% |
| Diarrhea | 8–13% | 8–20% |
| Vomiting | 6–13% | 5–24% |
| Constipation | 3–9% | 3–11% |
| Injection site reactions | <5% | <5% |
The COMING study found that gastrointestinal symptoms were more frequent with semaglutide, which may influence treatment choice for patients with prior GI intolerance. Dulaglutide showed superior diabetes treatment-related quality of life scores in that study, suggesting some patients find it easier to tolerate day-to-day.
For patients concerned about GI side effects, titrating slowly (starting at the lowest dose and increasing every 4 weeks) significantly reduces early intolerance with either drug. See the complete guide on GLP-1 side effects and management for detailed protocols.
Practical Considerations
Injection Device
Trulicity uses a single-use auto-injector pen with a pre-filled, hidden needle — many patients find it less intimidating than Ozempic's multi-dose pen. Ozempic requires needle attachment before each injection and dose dialing, which requires slightly more dexterity.
Refrigeration and Storage
Both drugs must be refrigerated (2–8°C) but can be kept at room temperature (up to 30°C) for a limited period — 14 days for Ozempic and 14 days for Trulicity. Review the full GLP-1 storage and handling guide for travel and temperature considerations.
Cost and Insurance
Both medications carry similar list prices (~$900–$1,000/month in the U.S. without insurance), though patient assistance programs, manufacturer coupons, and pharmacy benefit negotiations vary. Neither is approved by the FDA for obesity treatment — the branded obesity drug using semaglutide 2.4 mg is Wegovy; there is no dedicated obesity indication for dulaglutide.
Who Should Choose Which Drug?
Based on the available clinical evidence, general guidance is as follows:
Choose Ozempic (semaglutide) if:
- Weight loss is a primary goal (2–3.5 kg more weight reduction vs. dulaglutide)
- Maximum HbA1c reduction is the priority
- The patient is at high cardiovascular risk (secondary prevention)
- GI side effects are manageable or the patient has used GLP-1s before
Choose Trulicity (dulaglutide) if:
- The patient has no prior cardiovascular disease (primary prevention — REWIND data)
- GI tolerability is a significant concern
- Injection device simplicity is important
- The patient has already achieved adequate weight loss goals
No head-to-head trial has directly compared the cardiovascular outcomes of semaglutide versus dulaglutide. Treatment decisions should always incorporate individual patient factors, comorbidities, insurance coverage, and physician judgment.
Key Takeaways
- Both Trulicity and Ozempic are effective once-weekly GLP-1 receptor agonists for type 2 diabetes
- Ozempic produces approximately twice the weight loss of Trulicity at equivalent doses
- Ozempic achieves greater HbA1c reduction in most head-to-head comparisons
- Both drugs reduce cardiovascular events; semaglutide shows larger MACE reduction in secondary prevention, while dulaglutide has unique primary prevention data
- Trulicity may be better tolerated by some patients and has a simpler injection device
- Neither is FDA-approved for obesity — that indication belongs to Wegovy (semaglutide 2.4 mg)
References
Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. DOI: 10.1016/S2213-8587(18)30024-X
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. DOI: 10.1056/NEJMoa1607141
Li Z, et al. Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Biomed Rep. 2025. DOI: 10.3892/br.2024.1913
Iwakura T, et al. Comparison of clinical efficacy and safety of weekly GLP-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study). J Diabetes Investig. 2023. PubMed
Htike ZZ, et al. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:20420188211003650. PMC
Last updated: 2026-03-17 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Emily Rodriguez
Senior Medical Writer, MPH, RD
Emily Rodriguez is a registered dietitian and public health specialist. She translates complex medical research into accessible, actionable content for patients and healthcare providers.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.